Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment

Hye One Kim, Yoon Seok Yang, Hyun Chang Ko, Gyung Moon Kim, Sang Hyun Cho, Young Joon Seo, Sang Wook Son, Jong Rok Lee, Joong Sun Lee, Sung Eun Chang, Jae We Che, Chun Wook Park

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with lowdose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective: The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods: During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results: The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion: The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.

Original languageEnglish
Pages (from-to)523-530
Number of pages8
JournalAnnals of Dermatology
Volume27
Issue number5
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Seborrheic Dermatitis
Tacrolimus
Ointments
Placebos
Atopic Dermatitis
Disease Progression
Therapeutics
Recurrence
Placebo Effect
Research Personnel
Population

Keywords

  • Maintenance therapy
  • Seborrheic dermatitis
  • Tacrolimus ointment

ASJC Scopus subject areas

  • Dermatology

Cite this

Kim, H. O., Yang, Y. S., Ko, H. C., Kim, G. M., Cho, S. H., Seo, Y. J., ... Park, C. W. (2015). Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. Annals of Dermatology, 27(5), 523-530. https://doi.org/10.5021/ad.2015.27.5.523

Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. / Kim, Hye One; Yang, Yoon Seok; Ko, Hyun Chang; Kim, Gyung Moon; Cho, Sang Hyun; Seo, Young Joon; Son, Sang Wook; Lee, Jong Rok; Lee, Joong Sun; Chang, Sung Eun; Che, Jae We; Park, Chun Wook.

In: Annals of Dermatology, Vol. 27, No. 5, 01.10.2015, p. 523-530.

Research output: Contribution to journalArticle

Kim, HO, Yang, YS, Ko, HC, Kim, GM, Cho, SH, Seo, YJ, Son, SW, Lee, JR, Lee, JS, Chang, SE, Che, JW & Park, CW 2015, 'Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment', Annals of Dermatology, vol. 27, no. 5, pp. 523-530. https://doi.org/10.5021/ad.2015.27.5.523
Kim, Hye One ; Yang, Yoon Seok ; Ko, Hyun Chang ; Kim, Gyung Moon ; Cho, Sang Hyun ; Seo, Young Joon ; Son, Sang Wook ; Lee, Jong Rok ; Lee, Joong Sun ; Chang, Sung Eun ; Che, Jae We ; Park, Chun Wook. / Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. In: Annals of Dermatology. 2015 ; Vol. 27, No. 5. pp. 523-530.
@article{3101948fb7234e308041d5c975c099e8,
title = "Maintenance therapy of facial seborrheic dermatitis with 0.1{\%} tacrolimus ointment",
abstract = "Background: Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with lowdose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective: The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods: During the initial stabilization period, patients with facial SD or AD applied 0.1{\%} tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results: The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion: The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.",
keywords = "Maintenance therapy, Seborrheic dermatitis, Tacrolimus ointment",
author = "Kim, {Hye One} and Yang, {Yoon Seok} and Ko, {Hyun Chang} and Kim, {Gyung Moon} and Cho, {Sang Hyun} and Seo, {Young Joon} and Son, {Sang Wook} and Lee, {Jong Rok} and Lee, {Joong Sun} and Chang, {Sung Eun} and Che, {Jae We} and Park, {Chun Wook}",
year = "2015",
month = "10",
day = "1",
doi = "10.5021/ad.2015.27.5.523",
language = "English",
volume = "27",
pages = "523--530",
journal = "Annals of Dermatology",
issn = "1013-9087",
publisher = "Korean Dermatological Association",
number = "5",

}

TY - JOUR

T1 - Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment

AU - Kim, Hye One

AU - Yang, Yoon Seok

AU - Ko, Hyun Chang

AU - Kim, Gyung Moon

AU - Cho, Sang Hyun

AU - Seo, Young Joon

AU - Son, Sang Wook

AU - Lee, Jong Rok

AU - Lee, Joong Sun

AU - Chang, Sung Eun

AU - Che, Jae We

AU - Park, Chun Wook

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with lowdose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective: The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods: During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results: The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion: The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.

AB - Background: Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with lowdose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective: The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods: During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results: The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion: The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.

KW - Maintenance therapy

KW - Seborrheic dermatitis

KW - Tacrolimus ointment

UR - http://www.scopus.com/inward/record.url?scp=84943795524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943795524&partnerID=8YFLogxK

U2 - 10.5021/ad.2015.27.5.523

DO - 10.5021/ad.2015.27.5.523

M3 - Article

VL - 27

SP - 523

EP - 530

JO - Annals of Dermatology

JF - Annals of Dermatology

SN - 1013-9087

IS - 5

ER -